Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

MHCflurry: Open-Source Class I MHC Binding Affinity Prediction.

O'Donnell TJ, Rubinsteyn A, Bonsack M, Riemer AB, Laserson U, Hammerbacher J.

Cell Syst. 2018 Jul 25;7(1):129-132.e4. doi: 10.1016/j.cels.2018.05.014. Epub 2018 Jun 27.

2.

Computational Pipeline for the PGV-001 Neoantigen Vaccine Trial.

Rubinsteyn A, Kodysh J, Hodes I, Mondet S, Aksoy BA, Finnigan JP, Bhardwaj N, Hammerbacher J.

Front Immunol. 2018 Jan 18;8:1807. doi: 10.3389/fimmu.2017.01807. eCollection 2017.

3.

Somatic Mutations and Neoepitope Homology in Melanomas Treated with CTLA-4 Blockade.

Nathanson T, Ahuja A, Rubinsteyn A, Aksoy BA, Hellmann MD, Miao D, Van Allen E, Merghoub T, Wolchok JD, Snyder A, Hammerbacher J.

Cancer Immunol Res. 2017 Jan;5(1):84-91. doi: 10.1158/2326-6066.CIR-16-0019. Epub 2016 Dec 12.

4.

Using a Machine Learning Approach to Predict Outcomes after Radiosurgery for Cerebral Arteriovenous Malformations.

Oermann EK, Rubinsteyn A, Ding D, Mascitelli J, Starke RM, Bederson JB, Kano H, Lunsford LD, Sheehan JP, Hammerbacher J, Kondziolka D.

Sci Rep. 2016 Feb 9;6:21161. doi: 10.1038/srep21161.

5.

Mutation-Derived Tumor Antigens: Novel Targets in Cancer Immunotherapy.

Finnigan JP Jr, Rubinsteyn A, Hammerbacher J, Bhardwaj N.

Oncology (Williston Park). 2015 Dec;29(12):970-2, 974-5. Review. No abstract available.

Supplemental Content

Loading ...
Support Center